-
Mashup Score: 1Combining lenvatinib & pembrolizumab for non-clear cell RCC: KEYNOTE-B61 study rationale - 8 month(s) ago
Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights the rationale behind combining lenvatinib and pembrolizumab as a first-line treatment for non-clear cell renal cell carcinomas (RCC) in the Phase II KEYNOTE-B61 (NCT04704219) study. While most clinical trials have focused on clear cell RCC, a significant portion of patients have non-clear cell histologies, which historically have not responded well to existing systemic therapies. The combination of lenvatinib and pembrolizumab has shown impressive efficacy in clear cell RCC, prompting interest in exploring its potential benefits for non-clear cell histologies as well. The study aims to determine whether this combination therapy can be effective in improving outcomes for patients with non-clear cell RCC, offering a new treatment option for this subgroup of kidney cancer patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 8 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Did you know that September is Urological Cancer Awareness Month? 🤔 Visit https://t.co/ys1d8pDAKO for the latest in #GUCancer, such as our interview with @TiansterZhang on #ADCs in #BladderCancer and #ProstateCancer! 👉 https://t.co/3TSKtDngZj #Oncology #GUsm #PCsm #uroonc https://t.co/sGBqLc4Ud5
-
-
Mashup Score: 1
Ciara Conduit, FRACP, MBBS, PGCert MEd, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on updates from the CLIMATE trial (ACTRN12622000247774), which assessed the clinical utility of miR-371a-3p as a marker of residual disease in testicular cancer following orchiectomy. Having a post-operative biomarker will enable patients who test negative for minimal residual disease (MRD) to be spared treatment. Patients with seminoma and non-seminoma testicular cancer were recruited and the trial is currently ongoing. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@ciaraconduit from @PeterMacCC discusses promising updates from the CLIMATE trial, highlighting the potential of miR-371a-3p as a post-operative biomarker in testicular cancer: ➡️https://t.co/G8CbHIxyZk⬅️ #ANZUP23 #TSCSM #UroOnc #UroSoMe #CTSM
-
-
Mashup Score: 0Understanding variant histologies in urothelial carcinoma: IO and cabozantinib’s potential - 8 month(s) ago
Patrizia Giannatempo, MD, Foundation IRCCS National Cancer Institute, Milan, Italy, highlights the importance of understanding variant histologies in the context of treatment options for urothelial carcinoma, particularly immunotherapy and therapies like cabozantinib in neoadjuvant settings. Variant histologies in urothelial carcinoma often have limited alternatives compared to standard chemotherapy, and cystectomy is typically the first choice. However, emerging data from studies such as the Phase III KEYNOTE-045 (NCT02256436) and Phase II ARCADIA (NCT03824691) trials indicate that the treatment landscape for variant histologies could potentially change in the future. It is crucial to identify which subtypes of variants could benefit from pembrolizumab or the combination of durvalumab and cabozantinib. While the Arcadia trial is still ongoing and requires completion with 120 treated patients, the preliminary results are promising, indicating the need to further explore and understand
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@giannatempopatr emphasizes understanding variant histologies in UC treatment. Emerging data from trials like KEYNOTE-045 & ARCADIA could change the landscape for these variants: ➡️https://t.co/8Dm3BqClO2⬅️ #ASCO23 #BlcSM #CTSM #UroOnc #UroSoMe
-
-
Mashup Score: 0
Shawn Dason, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, talks on the role of cytoreductive nephrectomy and metastasectomy in renal cell carcinoma (RCC). The use of cytoreductive nephrectomy has evolved with the availability of better systemic therapies, and patient and disease factors should be considered when determining its suitability. Systemic therapy followed by deferred cytoreductive nephrectomy is an option supported by recent randomized data. Metastasectomy is also approached on an individual basis, considering factors such as solitary site involvement, limited morbidity, and a lower likelihood of quick recurrence. Palliative reasons and alternative treatments like stereotactic body radiotherapy (SBRT) are also discussed in the context of metastasectomy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by co
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@shawndason of @OSUCCC_James discusses the evolving role of cytoreductive nephrectomy & metastasectomy in RCC. Patient factors, systemic therapies, & individualized approaches play a key role: ➡️https://t.co/oSb2DSYHD8⬅️ #ASC023 #kcsm #UroOnc #UroSoMe
-
-
Mashup Score: 0
Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the future of erdafitinib in the treatment landscape for metastatic urothelial carcinoma. Frontline treatments for metastatic urothelial carcinoma remain an unmet need, where approximately half of patients are not eligible for the standard of care. Findings from the Phase III THOR trial (NCT03390504) confirmed the promising benefits of erdafitinib, and additional studies will compare the drug to existing therapies such as gemcitabine with carboplatin, or enfortumab vedotin plus pembrolizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥Arlene O. Siefker-Radtke, MD, of @MDAndersonNews discusses erdafitinib's potential in metastatic urothelial carcinoma treatment, addressing unmet needs and ongoing trials: ➡️https://t.co/IdwkDSG632⬅️ #ASCO23 #Blcsm #UroOnc #UroSoMe
-
-
Mashup Score: 0Integrating patients’ experiences in bladder cancer therapeutic decisions: challenges and solutions - 8 month(s) ago
Benjamin Garmezy, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the challenges in effectively integrating patients’ experiences into therapeutic decisions in bladder cancer and how these can be addressed. One key challenge is the limited time available for discussions between healthcare professionals and patients, which can hinder the comprehensive exploration of patient perspectives. Additionally, the complexity of medical information and terminology may impede effective communication. To address these challenges, healthcare professionals can allocate sufficient time for discussions, employ patient-friendly language, and utilize decision aids or support tools. Moreover, fostering a culture of shared decision-making and actively involving patients in treatment planning can ensure that their voices are adequately represented and their preferences are considered. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago,
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@BGarmezy (@SarahCannonDocs) discusses challenges in integrating patient experiences into bladder cancer therapeutic decisions and solutions. Time allocation, patient-friendly language, and decision aids are key: ➡️https://t.co/9ioNxvAWAw⬅️ #ASCO23 #BlcSM #UroOnc #UroSoMe
-
-
Mashup Score: 0
Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, discusses findings from the Phase II STARTAR trial (NCT03311555) of androgen receptor inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy followed by docetaxel in patients with PSA recurrent prostate cancer. 3-year progression-free survival was increased after treatment, demonstrating the clinical feasibility of intensifying systemic treatments for PSA recurrent prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@TiansterZhang of @utsw highlights Phase II STARTAR trial results, showing improved 3-year PFS in PSA recurrent prostate cancer with intensified treatment: ➡️https://t.co/3ef6cSGqvv⬅️ #ASCO23 #PCSM #UroOnc #UroSoMe #CTSM #TrialUpdate
-
-
Mashup Score: 2Study shows promise of immunotherapy treatment for penile cancer - 8 month(s) ago
“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma,” said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.
Source: www.urologytimes.comCategories: Latest Headlines, UrologyTweet-
“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," says Dr. Amin Nassar. #urology #urologist #uroonc Read more on the study here: https://t.co/XxRTxUQ1Ga
-
-
Mashup Score: 0Targeted radionuclide therapy in prostate cancer - 9 month(s) ago
Prostate cancer stands as the most frequently detected malignant condition among men, ranking as the second primary contributor to cancer-linked…
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎧In this podcast, we hear from @CalaisJeremie (@UofCalifornia), @DrScottTagawa (@WeillCornell)& @SandhuShahneen (@PeterMacCC) as they share insights and updates in radionuclide therapy for prostate cancer: Listen here➡️https://t.co/B0SJvj9Zvz⬅️ #PCsm #UroOnc #UroSoMe https://t.co/CglHPv5MeY
-
🎥@ChungHanLee3 of @MSKCancerCenter explores the synergy of lenvatinib and pembrolizumab in treating non-clear cell RCC, offering new hope for kidney cancer patients. Learn more here: ➡️https://t.co/nNKpxxGe9V⬅️ #ASCO23 #ImmunoOnc #KCSM #UroOnc #UroSoMe